Sonic Incytes was recognized as a “Company to Watch” at the 25th Annual LSBC Awards Gala, presented by Farris. This

Velacur™️ ACE Outperforms FibroScan®️ CAP for Liver Fat Quantification We are excited to announce that clinical data from Sonic Incytes’

Sonic Incytes is pleased to announce they have received Food and Drug Administration (FDA) clearance for new Organ Guide and

Sonic Incytes Medical Corp. is pleased to announce its project was selected for investment by the inaugural INOVAIT Focus Fund.

Sonic Incytes Medical Corp. is pleased to announce clinical data from a prospective multi-center study comparing the effectiveness of Velacur™️

Sonic Incytes Medical Corp. is pleased to announce the inclusion of Velacur™️ — the first handheld 3D liver health assessment tool—in

The poster entitled “Accuracy of Velacur™️ AI Powered Liver Guide in Identification of Liver” presented at the Digestive Disease Week

Metabolic syndrome is a cluster of conditions that increase the risk of many chronic illnesses such as heart disease, stroke,

Sonic Incytes Medical Corp. is pleased to host a live educational webinar on Novel Tools for Managing Metabolic Syndrome. Metabolic

Following the closing of its US$7.3M Series A raise in December 2021, the Sonic Incytes Medical Corp. Board of Directors

Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its

Join us virtually on December 1 at 10AMPT/12PM CT/1PM ET at the 5th Annual NASH Summit 2021 to learn about

Sonic Incytes Medical Corp. has been selected as one of three finalists at the ADA’s 2021 Silicon Valley Leaders Forum

Sonic Incytes Medical Corp. is pleased to host a live educational webinar on Owning NAFLD Via Reimbursement Optimization. Join former

There is a certain thrill when you find parts and use them to build something new. For Sonic Incytes’ Lead

Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first

In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld

You’re invited! Join Sonic Incytes at ACG 2021. VelacurTM, the first handheld 3D liver health assessment solution, is coming to

If you practice in the field of liver disease, visit our booth at the 16th Annual National Liver Conference to

VelacurTM, the first handheld 3D liver health assessment solution, is coming to the 2021 Annual TSGE Conference, September 24 to